Ilia I. Ouspenski

Array ( [id] => 13970485 [patent_doc_number] => 10214585 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-02-26 [patent_title] => Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS [patent_app_type] => utility [patent_app_number] => 14/850794 [patent_app_country] => US [patent_app_date] => 2015-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 56 [patent_no_of_words] => 21054 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 129 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14850794 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11269234 [patent_doc_number] => 20160331781 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-17 [patent_title] => 'ACTIVATION OF MARROW INFILTRATING LYMPHOCYTES IN HYPOXIC ALTERNATING WITH NORMOXIC CONDITIONS' [patent_app_type] => utility [patent_app_number] => 15/112353 [patent_app_country] => US [patent_app_date] => 2015-09-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 6871 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15112353 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11025162 [patent_doc_number] => 20160222117 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-08-04 [patent_title] => 'NUCLEIC ACID ENCODING ANTI-PD-L1 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/846457 [patent_app_country] => US [patent_app_date] => 2015-09-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 66180 [patent_no_of_claims] => 85 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14846457 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10750739 [patent_doc_number] => 20160096890 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-04-07 [patent_title] => 'B7-H1, A NOVEL IMMUNOREGULATORY MOLECULE' [patent_app_type] => utility [patent_app_number] => 14/845020 [patent_app_country] => US [patent_app_date] => 2015-09-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 17765 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14845020 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10750738 [patent_doc_number] => 20160096889 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-04-07 [patent_title] => 'B7-H1, A NOVEL IMMUNOREGULATORY MOLECULE' [patent_app_type] => utility [patent_app_number] => 14/844914 [patent_app_country] => US [patent_app_date] => 2015-09-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 17762 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14844914 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10714197 [patent_doc_number] => 20160060344 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-03 [patent_title] => 'COMBINATION THERAPY FOR PD-L1 NEGATIVE TUMORS' [patent_app_type] => utility [patent_app_number] => 14/838650 [patent_app_country] => US [patent_app_date] => 2015-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 10638 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14838650 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12490614 [patent_doc_number] => 09994818 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-06-12 [patent_title] => ICOS critically regulates the expansion and function of inflammatory human Th17 cells [patent_app_type] => utility [patent_app_number] => 14/823281 [patent_app_country] => US [patent_app_date] => 2015-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 13 [patent_no_of_words] => 23639 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14823281 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10791575 [patent_doc_number] => 20160137731 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-19 [patent_title] => 'HUMAN ANTI-PD-1, PD-L1, AND PD-L2 ANTIBODIES AND USES THEREFOR' [patent_app_type] => utility [patent_app_number] => 14/822651 [patent_app_country] => US [patent_app_date] => 2015-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 42 [patent_no_of_words] => 41745 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14822651 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11805193 [patent_doc_number] => 09546206 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-01-17 [patent_title] => 'High affinity PD-1 agents and methods of use' [patent_app_type] => utility [patent_app_number] => 14/821589 [patent_app_country] => US [patent_app_date] => 2015-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 52 [patent_no_of_words] => 45239 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14821589 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10693981 [patent_doc_number] => 20160040127 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-11 [patent_title] => 'USE OF LIGANDS FOR THE PROGRAMMED CELL DEATH RECEPTOR CONJUGATED TO SOLID SUPPORTS FOR THE EXPANSION OF HUMAN REGULATORY T CELLS' [patent_app_type] => utility [patent_app_number] => 14/820795 [patent_app_country] => US [patent_app_date] => 2015-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 8435 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14820795 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17251168 [patent_doc_number] => 11186640 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-30 [patent_title] => Method for the identification of immunotherapy-drug combinations using a network approach [patent_app_type] => utility [patent_app_number] => 15/500498 [patent_app_country] => US [patent_app_date] => 2015-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 18 [patent_no_of_words] => 12819 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15500498 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10670894 [patent_doc_number] => 20160017039 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-21 [patent_title] => 'USE OF AN ACTIVE SUBSTANCE BINDING TO CD28 FOR PRODUCING A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF B-CLL' [patent_app_type] => utility [patent_app_number] => 14/813881 [patent_app_country] => US [patent_app_date] => 2015-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 5461 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14813881 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10506177 [patent_doc_number] => 09234043 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2016-01-12 [patent_title] => 'Anti-human OX40L antibodies' [patent_app_type] => utility [patent_app_number] => 14/811163 [patent_app_country] => US [patent_app_date] => 2015-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 7 [patent_no_of_words] => 67649 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14811163 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10729632 [patent_doc_number] => 20160075782 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-17 [patent_title] => 'HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1)' [patent_app_type] => utility [patent_app_number] => 14/807522 [patent_app_country] => US [patent_app_date] => 2015-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 61 [patent_figures_cnt] => 61 [patent_no_of_words] => 44074 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14807522 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10729632 [patent_doc_number] => 20160075782 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-17 [patent_title] => 'HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1)' [patent_app_type] => utility [patent_app_number] => 14/807522 [patent_app_country] => US [patent_app_date] => 2015-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 61 [patent_figures_cnt] => 61 [patent_no_of_words] => 44074 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14807522 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10729632 [patent_doc_number] => 20160075782 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-17 [patent_title] => 'HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1)' [patent_app_type] => utility [patent_app_number] => 14/807522 [patent_app_country] => US [patent_app_date] => 2015-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 61 [patent_figures_cnt] => 61 [patent_no_of_words] => 44074 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14807522 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10729632 [patent_doc_number] => 20160075782 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-17 [patent_title] => 'HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1)' [patent_app_type] => utility [patent_app_number] => 14/807522 [patent_app_country] => US [patent_app_date] => 2015-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 61 [patent_figures_cnt] => 61 [patent_no_of_words] => 44074 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14807522 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10714195 [patent_doc_number] => 20160060343 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-03 [patent_title] => 'CANCER TREATMENT' [patent_app_type] => utility [patent_app_number] => 14/805854 [patent_app_country] => US [patent_app_date] => 2015-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 11575 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14805854 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12099229 [patent_doc_number] => 09856318 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-01-02 [patent_title] => 'Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS' [patent_app_type] => utility [patent_app_number] => 14/797894 [patent_app_country] => US [patent_app_date] => 2015-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 56 [patent_no_of_words] => 21335 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14797894 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10548524 [patent_doc_number] => 09273135 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-03-01 [patent_title] => 'Human monoclonal antibodies to programmed death ligand 1 (PD-L1)' [patent_app_type] => utility [patent_app_number] => 14/796956 [patent_app_country] => US [patent_app_date] => 2015-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 61 [patent_figures_cnt] => 65 [patent_no_of_words] => 44079 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 465 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14796956 [rel_patent_id] =>[rel_patent_doc_number] =>)